SCHEMBL4215918

SCHEMBL4215918

CCCCOc1cc(/C=C(/C)C(=O)O)ccc1I

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
AKR1C3 P42330 2/20 0.41
ALOX5 P09917 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
PLA2G4A P47712 2/20 0.39
XDH P47989 1/20 0.39
PTGES O14684 1/20 0.38
PPARG P37231 1/20 0.38
TUBB4A P04350 2/20 0.38
TUBB P07437 2/20 0.38
TUBA3C P0DPH7 2/20 0.38
TUBA1B P68363 2/20 0.38
TUBA4A P68366 2/20 0.38
TUBB4B P68371 2/20 0.38
TUBB3 Q13509 2/20 0.38
HDAC1 Q13547 2/20 0.38
TUBB2A Q13885 2/20 0.38
TUBB8 Q3ZCM7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68302 1.00 KDM4E (0.42) KDM4EAKR1C3ALOX5KMT2AMEN1
SCHEMBL68303 1.00 KDM4E (0.42) KDM4EAKR1C3ALOX5KMT2AMEN1
SCHEMBL4219853 0.95 KDM4E (0.47) KDM4EAKR1C3KMT2AMEN1GAA
SCHEMBL4219857 0.95 KDM4E (0.47) KDM4EAKR1C3KMT2AMEN1GAA
SCHEMBL4223938 0.87 AKR1C3 (0.39) KDM4EAKR1C3KMT2AMEN1GAA
SCHEMBL2891475 0.87 TUBB4A (0.41) KDM4EAKR1C3KMT2AGAAPLA2G4A
SCHEMBL4607835 0.87 AKR1C3 (0.39) KDM4EAKR1C3KMT2AMEN1GAA
SCHEMBL4218503 0.87 AKR1C3 (0.39) KDM4EAKR1C3KMT2AMEN1GAA
SCHEMBL4220644 0.86 ALOX5 (0.47) KDM4EAKR1C3ALOX5XDHPTGES
SCHEMBL4212795 0.86 ALOX5 (0.47) KDM4EAKR1C3ALOX5XDHPTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA KDM4E 2728/4885AKR1C3 901/4885ALOX5 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.